Old Web
English
Sign In
Acemap
>
authorDetail
>
A Gaur
A Gaur
Novartis
in patient
Medicine
Cancer
Oncology
advanced breast
2
Papers
5
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Preliminary Results from a Phase Ib Study Exploring MDM2 Inhibitor Siremadlin (HDM201) in Combination with B-Cell Lymphoma-2 (BCL-2) Inhibitor Venetoclax in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS)
2021
Blood
Andrew H. Wei
Massimo Breccia
Melissa Ooi
María Teresa Cedena Romero
Fabio Ciceri
Harry P. Erba
A Gaur
Romain Sechaud
Ensar Halilovic
Brigitte Kuenzle
Claire Fabre
Kimmo Porkka
Show All
Source
Cite
Save
Citations (0)
Overall survival (OS) in patients (pts) with advanced breast cancer (ABC) with visceral metastases (mets), including those with liver mets, treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA (ML) -3 and -7 trials.
2020
Journal of Clinical Oncology
Denise A. Yardley
Arnd Nusch
Yoon Sim Yap
Gabe S. Sonke
Thomas Bachelot
Arlene Chan
Patrick Neven
Dennis J. Slamon
Paul Wheatley-Price
Agnes Lteif
Manu Sondhi
Karen Rodriguez-Lorenc
A Gaur
Stephen Chia
Show All
Source
Cite
Save
Citations (5)
1